A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

Cancer Gene Therapy

Volumn 9, Issue 7, 2002, Pages 553-566

  Buller, Richard E ^a   Runnebaum, Ingo B ^b   Karlan, Beth Y ^c   Horowitz, Jo Ann ^d   Shahin, Mark ^a   Buekers, Thomas ^a   Petrauskas, Stan ^d   Kreienberg, Rolf ^e   Slamon, Dennis ^c   Pegram, Mark ^c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

CA125; Gene therapy; Ovarian cancer; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL; VIRUS DNA; DEXAMETHASONE; PLATINUM; PROTEIN P53; SCH 58500; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; BIOSYNTHESIS; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MUTATION; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TRANSGENE; TUMOR SUPPRESSOR GENE; UTERINE TUBE TUMOR; ABDOMINAL DISEASE; ADULT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; FEVER; GENE REPLACEMENT THERAPY; HYPOTENSION; IMMUNE RESPONSE; NAUSEA; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; RECURRENT CANCER; UTERINE TUBE CARCINOMA; VIRUS RECOMBINANT; VOMITING;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CA-125 ANTIGEN; CARBOPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENE THERAPY; GENES, P53; HUMANS; MUTATION; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRANSGENES; HUMAN;

ADENOVIRIDAE; FALLOPIA;

EID: 0036019371     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700472     Document Type: Article

References (75)

1. Cancer statistics, 2001
2. Brain metastases in epithelial ovarian carcinoma
3. Distant metastases in ovarian cancer: Why do they occur?
4. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma
5. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
6. Evaluation of treatment and survival after positive second-look laparotomy
7. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma
8. The p53 tumour suppressor gene
9. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
10. Apoptosis, cancer and the p53 tumour suppressor gene
11. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
12. Tumor-suppressor p53: Implications for tumor development and prognosis
13. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
14. P53 mutations and expression in ovarian cancers: Correlation with overall survival
15. An abundance of p53 null mutations in ovarian carcinoma
16. The prognostic significance of p53 tumor suppressor gene alterations in ovarian cancer
17. Theoretical and experimental bases of intraperitoneal chemotherapy
18. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
19. Gene therapy: Ovarian carcinoma as the paradigm
20. New horizons: Gene therapy for cancer
21. Recombinant El-deleted adenovirus-mediated gene therapy for cancer: Efficacy studies with p53 tumor suppressor gene and liver histology in mouse tumor xenograft models
22. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
23. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts
24. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
25. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer
26. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse
27. P53 gene therapy in a rat model for hepatocellular carcinoma: Intra-arterial delivery of a recombinant adenovirus
28. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer
29. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
30. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus
31. Retrovirus-mediated wild-type gene transfer to tumors of patients with lung cancer
32. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
33. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
34. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
35. High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus
36. P53 tumor suppressor gene therapy for cancer
37. A phase I/II trial of recombinant adenoviral human p53 (SCH 58500) intraperitoneal (IP) gene therapy in recurrent ovarian cancer
38. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer
39. Prediction of creatinine clearance from serum creatinine
40. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
41. Use of tumour markers in monitoring the course of ovarian cancer
42. A comparison of flow cytometry and laser scanning cytometry for the intracellular evaluation of adenoviral infectivity and p53 protein expression in gene therapy
43. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status
44. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma
45. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck
46. Genetic mechanisms of tumor suppression by the human p53 gene
47. Gene therapeutics and gene therapy for cancer
48. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin
49. Intraperitoneal interferon-α in residual ovarian carcinoma: A phase II gynecologic oncology group study
50. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer - Long-term follow-up
51. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment
52. Intraperitoneal mitoxantrone or floxuridine: Effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy - A randomized phase II study by the Southwest Oncology Group
53. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer
54. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group Study
55. A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer
56. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients
57. Thymidine kinase (TK) gene therapy of solid tumors: Valacyclovir facilitates outpatient treatment
58. A phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer
59. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer
60. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability
61. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies
62. Human adenovirus vectors for gene transfer into mammalian cells
63. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
64. Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy
65. Expression of coxsackie and adenovirus receptor (CAR) correlates with efficiency of adenovirus transduction of human ovarian carcinoma cells
66. CA 125 regression: A model for epithelial ovarian cancer response
67. CA125 kinetics: A cost effective clinical tool to evaluate clinical trial outcomes in the 1990s
68. Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy
69. Use of CA-125 to predict survival of patients with ovarian carcinoma
70. CA125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery
71. The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125
72. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer
73. Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells
74. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy